今日聚焦 1、露笑科技：筹划发行H股股票并在香港联交所上市 露笑科技(002617.SZ)公告称，公司正在筹划境外发行股份(H股)并在香港联合交易所有限公司上市，以 推进全球化战略布局，打造国际化资本运作平台，提升国际品牌形象和综合竞争力。相关细节尚未确 定，待具体方案确定后，尚需提交公司董事会和股东大会审议，并经中国证券监督管理委员会备案和香 港联交所等监管机构审核。该事项具有较大不确定性，公司将及时履行信息披露义务。 2、山河智能：全资子公司收到保险赔付款 影响净利润金额1.26亿元 山河智能公告，公司全资子公司AVMAX曾与俄罗斯客户签订三份飞机租赁合同。自2022年2月地缘政 治冲突以来，航空业在制裁范围内。AVMAX根据相关政策，多次尝试召回上述租赁在俄罗斯的飞机。 尽管已持续进行交涉与回收操作，仍无法成功收回涉事飞机。近日，AVMAX与飞机保险承保人就赔付 方案达成一致意见，确认AVMAX可从保险承保商获得的保险理赔款为2900万美元，扣除律师费用等后 的保险赔付款净额为2296.51万美元。截至目前，AVMAX已全额收到2296.51万美元保险赔付款，按照8 月8日美元对人民币汇率中间价，折算人 ...

证券代码：600200 证券简称：*ST 苏吴 公告编号：临 2025-082 江苏吴中医药发展股份有限公司关于就 Regen Biotech,Inc.违约提起仲裁并被受理立案的公告 一、申请仲裁的基本情况 1、案件号：（2025）深国仲涉外受 8781 号 江苏吴中医药发展股份有限公司(以下简称"公司")控股孙公司达透医 疗器械（上海）有限公司（以下简称"达透医疗"）就 Regen Biotech, Inc.违约事项向深圳国际仲裁院提起仲裁，并于 2025 年 8 月 7 日获得深 圳国际仲裁院受理立案。达透医疗仲裁请求确认《独家代理协议》有效 并继续履行，若上述仲裁请求未得到支持，初步索赔损失人民币 16 亿元 （包括但不限于已经投入的相关市场开发成本损失，因无法向终端客户 供货而发生的违约损失，以及合同期内可得利益损失等），并保留根据 案情进展及其他相关因素对前述索赔金额进行调整的权利。 本次仲裁将按照《深圳国际仲裁院仲裁规则》进行，仲裁结果存在不确 定性，同时不排除仲裁被申请人提出仲裁反请求的可能性。目前，公司 无法正常继续销售 AestheFill，敬请广大投资者注意投资风险。 2025 年 7 月 ...

每经AI快讯，8月11日，*ST苏吴(600200.SH)公告称，公司控股孙公司达透医疗器械（上海）有限公司 就Regen Biotech, Inc.违约事项向深圳国际仲裁院提起仲裁，并于2025年8月7日获得受理立案。达透医疗 请求确认《独家代理协议》有效并继续履行，若未得到支持，初步索赔损失人民币16亿元。仲裁结果存 在不确定性，且不排除被申请人提出反请求。此外，公司股票因收到《行政处罚事先告知书》被叠加实 施退市风险警示，可能存在炒作风险。 ...

Group 1 - The stock price of *ST Suwu (600200) closed at 1.07 yuan, down 5.31%, with a turnover rate of 11.7% and a trading volume of 831,600 hands, amounting to 89.54 million yuan [1] - The latest financial report for *ST Suwu shows total operating revenue of 317 million yuan, a year-on-year decrease of 25.44%, and a net profit attributable to shareholders of 70.32 million yuan, a decrease of 1,489.93% year-on-year [1] - The company has a current ratio of 1.477, a quick ratio of 1.426, and a debt-to-asset ratio of 54.16% [1] Group 2 - Jiangsu Wuzhong Pharmaceutical Development Co., Ltd. was established in 1994 and is primarily engaged in the pharmaceutical manufacturing industry, located in Suzhou [2] - The company has made investments in 12 enterprises and participated in 5 bidding projects, holding 47 trademark registrations and 2 patents [2]

Group 1 - The average stock price of A-shares is 12.58 yuan, with 36 stocks priced below 2 yuan, the lowest being *ST Suwu at 1.07 yuan [1] - Among the low-priced stocks, 12 are ST stocks, accounting for 33.33% of the total [1] - In terms of market performance, 25 of the low-priced stocks increased in price, with *ST Tianmao, ST Zhongzhu, and Beichen Industrial leading the gains at 4.83%, 4.07%, and 3.87% respectively [1] Group 2 - The lowest priced stocks include *ST Suwu (1.07 yuan), *ST Jinke (1.42 yuan), and Rongsheng Development (1.43 yuan) [1] - The trading volume for *ST Suwu shows a turnover rate of 11.70%, while *ST Tianmao has a turnover rate of 1.50% [1] - The stock price performance of low-priced stocks indicates a mixed trend, with some experiencing gains while others faced declines [1][2]

Group 1 - Several A-share listed companies are facing delisting risks due to suspected financial fraud or information disclosure violations, with *ST Zitian, *ST Suwu, *ST Tianmao, and *ST Gaohong being the focus of investor attention [1] - *ST Gaohong has been subjected to mandatory delisting procedures by the Shenzhen Stock Exchange due to serious financial fraud and has incurred an administrative fine of 160 million yuan [1] - *ST Tianmao announced its intention to voluntarily withdraw its A-shares from trading on the Shenzhen Stock Exchange through a shareholders' meeting resolution [1] Group 2 - A total of 23 companies have been delisted from the A-share market this year, primarily due to financial-related delisting, trading-related delisting, major illegal mandatory delisting, and voluntary delisting [2] - Companies such as Zhonghang Chanyin and Yulong Co. are categorized as voluntary delisting, while companies like Tuishe Zhuolang and Tuishe Jinguang are classified under major illegal mandatory delisting [2] - Several companies, including *ST Furun, *ST Dongfang, *ST Xulan, *ST Jiayu, and *ST Jiyuan, have been delisted due to stock prices falling below par value [2]

Group 1 - The stock exchange has implemented monitoring measures for stocks that exhibit significant abnormal fluctuations in trading, particularly focusing on large buy or sell orders within a one-minute period during continuous bidding phases [1] Group 2 - A list of stocks under abnormal fluctuation monitoring includes Dongxin Co., North Long Chuang, and Xizang Tourism, with monitoring periods ranging from early July to late August 2025 [2][3] - Specific monitoring dates for Dongxin Co. are from August 8 to August 21, with the abnormal fluctuation starting on July 25 [2] - Other stocks like Happiness Blue Sea and Shangwei New Materials also have defined monitoring periods, indicating a broader trend of scrutiny on stocks with unusual trading patterns [2][3]

New Stock Listings - Tianfu Long (603406) issued at a price of 23.60[1] - Youli Intelligent (920007) issued at a price of 23.99[1] Rights Issues and Announcements - China Heavy Industry (601989) cash option declaration period from August 13, 2025[1] - China Shipbuilding (600150) acquisition request period from August 13 to August 15, 2025[1] - Shenkai Co., Ltd. (002633) offer declaration period from July 29 to August 27, 2025[1] - ST Kelly (300326) offer period from July 17 to August 15, 2025[1] - Fushun Special Steel (600399) offer period from August 12 to September 10, 2025[1] Abnormal Fluctuations - Multiple stocks reported abnormal fluctuations, including *ST Yushun (002289) and Changcheng Military Industry (601606)[2][3] - Notable fluctuations also reported for companies like Li De Man (300289) and Dongjie Intelligent (300486)[3]

Core Viewpoint - The dispute over the exclusive agency rights for the "童颜针" (AestheFill) between *ST Suwu and Aimeike highlights the lucrative nature of the medical beauty industry, particularly the significant revenue generated by AestheFill for *ST Suwu, which could be jeopardized by the termination of the agency agreement [1][2][8]. Group 1: Agency Dispute - Aimeike announced the termination of the exclusive distribution agreement for AestheFill, which affects *ST Suwu's subsidiary, Datuo Medical, potentially leading to a loss of significant revenue [2][3]. - The reasons for the termination include alleged violations of the agreement by Datuo Medical and serious legal issues faced by *ST Suwu's executives, which have impacted the reputation of AestheFill in China [3][5]. - *ST Suwu refuted these claims, asserting that there was no transfer of agency rights and that the termination was unjustified, indicating potential legal actions against Aimeike [5][6]. Group 2: Financial Impact - AestheFill contributed over 3 billion yuan in revenue to *ST Suwu within a year, representing a 4000% increase in the medical beauty segment's performance [1][8]. - If the agency agreement is terminated, *ST Suwu anticipates a significant decline in revenue and profit from its medical beauty segment, with AestheFill projected to account for 20.42% of total revenue in 2024 [8][11]. - Aimeike's corresponding product, "濡白天使," has also shown strong performance, with revenues increasing from 385 million yuan in 2021 to 1.216 billion yuan in 2024, indicating robust growth in the medical beauty market [13]. Group 3: Market Dynamics - The medical beauty injection market, particularly for products like AestheFill, is expected to grow rapidly, with projections estimating a market size of 11.52 billion yuan by 2027 and a compound annual growth rate of 54.73% from 2021 to 2025 [9]. - The competition in the "童颜针" market is intensifying, with multiple players entering the space, including products from Aimeike, Korean REGEN, and others, indicating a crowded and competitive landscape [15].

证券代码：600200 证券简称：*ST 苏吴 公告编号：临 2025-081 江苏吴中医药发展股份有限公司关于公司股票 可能被实施重大违法强制退市的第五次风险提示公告 本公司董事会及董事会全体成员保证公告内容不存在虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实、准确和完整承担法律责任。 重要风险提示： 2、根据《上海证券交易所股票上市规则》第 9.5.7 条、第 9.5.8 条，如公 司后续收到行政处罚决定书，显示公司触及重大违法类强制退市情形，公司将申 请停牌，并及时披露有关内容。上海证券交易所将在停牌之日起的 5 个交易日内， 向公司发出拟终止股票上市的事先告知书，后续将根据《上海证券交易所股票上 市规则》的相关规定，作出是否终止公司股票上市的决定。 公司指定信息披露媒体为《中国证券报》《上海证券报》以及上海证券交易 所网站（www.sse.com.cn），有关公司的信息均以上述指定媒体刊登的信息为准。 敬请投资者注意投资风险。 特此公告。 江苏吴中医药发展股份有限公司(以下简称"公司")因涉嫌信息披露违 法违规，被中国证券监督管理委员会（以下简称"中国证监会"）立案 调查。2025 年 7 月 ...